Newsroom

latest news from ose
and across our portfolio

Featured News

Oxford Spinout Oxford Semantic Technologies acquired by Samsung Electronics
Oxford Spinout Oxford Semantic Technologies acquired by Samsung ElectronicsArticle links to www.oxionics.com
Oxford Ionics breaks global quantum performance records
Oxford Ionics breaks global quantum performance records
Times Commentary: Science innovation must be at the heart of government action
Times Commentary: Science innovation must be at the heart of government actionArticle links to www.beacontx.com
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene TherapiesArticle links to www.prnewswire.com
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptography
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptographyArticle links to www.globenewswire.com
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raises
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raisesArticle links to www.businesswire.com
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group

All News

Portfolio NewsEvox TherapeuticsEvox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerPortfolio NewsEvox TherapeuticsLandmark paper in Nature Communications highlights continued advances in Evox Therapeutics’s proprietary exosome engineering platformPortfolio NewsEvox TherapeuticsEvox Therapeutics enters into agreement to advance next generation exosome-delivered AAV gene therapy for the treatment of heart diseasePortfolio NewsEvox TherapeuticsEvox Therapeutics Acquires Exosome AAV Technology and Intellectual PropertyPortfolio NewsEvox TherapeuticsEvox Therapeutics granted key US exosome purification patentPortfolio NewsEvox TherapeuticsEvox Therapeutics expands its exosome patent portfolioPortfolio NewsEvox TherapeuticsLandmark paper highlights Evox Therapeutics’ cutting edge exosome engineering approach for enhanced surface display of biologicsPortfolio NewsEvox TherapeuticsEvox Therapeutics completes £69.2 million Series C financingPortfolio NewsEvox TherapeuticsJohn McHutchison joins the board of Evox TherapeuticsPortfolio NewsEvox TherapeuticsEvox Therapeutics announces launch of strategic collaboration with the University of Oxford